{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T18:18:42Z","timestamp":1648923522538},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,8,22]],"date-time":"2009-08-22T00:00:00Z","timestamp":1250899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s12185-009-0405-3","type":"journal-article","created":{"date-parts":[[2009,8,21]],"date-time":"2009-08-21T02:08:52Z","timestamp":1250820532000},"page":"416-420","source":"Crossref","is-referenced-by-count":1,"title":["Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia"],"prefix":"10.1007","volume":"90","author":[{"given":"Takuji","family":"Yamauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Kamezaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takatoshi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asataro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,22]]},"reference":[{"key":"405_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2006.11.024","volume":"13","author":"B Oran","year":"2007","unstructured":"Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007;13:454\u201362.","journal-title":"Biol Blood Marrow Transplant"},{"key":"405_CR2","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092\u20139.","journal-title":"Blood"},{"key":"405_CR3","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"C Schmid","year":"2007","unstructured":"Schmid C, Labopin M, Nagler A, Bornh\u00e4user M, Finke J, Fassas A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938\u201345.","journal-title":"J Clin Oncol"},{"key":"405_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2006-05-021907","volume":"109","author":"E Estey","year":"2007","unstructured":"Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395\u2013400.","journal-title":"Blood"},{"key":"405_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","volume":"104","author":"M Lima de","year":"2004","unstructured":"de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865\u201372.","journal-title":"Blood"},{"key":"405_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19:176\u201382.","journal-title":"Leukemia"},{"key":"405_CR7","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, L\u00f6wenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442\u201352.","journal-title":"Cancer"},{"key":"405_CR8","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578\u201382.","journal-title":"Blood"},{"key":"405_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.leu.2405014","volume":"22","author":"M Lima de","year":"2008","unstructured":"de Lima M, Champlin RE, Thall PF, Wang X, Martin III TG, Cook JD, et al. Phase I\/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008;22:258\u201364.","journal-title":"Leukemia"},{"key":"405_CR10","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-08-0894","volume":"14","author":"M Bornh\u00e4user","year":"2008","unstructured":"Bornh\u00e4user M, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, et al. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. Clin Cancer Res. 2008;14:5585\u201393.","journal-title":"Clin Cancer Res"},{"key":"405_CR11","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396\u2013404.","journal-title":"Haematologica"},{"key":"405_CR12","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-03-0754","volume":"10","author":"S Miyakoshi","year":"2004","unstructured":"Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res. 2004;10:3586\u201392.","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-009-0405-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0405-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-009-0405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:01:27Z","timestamp":1559451687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-009-0405-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,22]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["405"],"URL":"https:\/\/doi.org\/10.1007\/s12185-009-0405-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,22]]}}}